Neoplasia of the tongue in a patient with Crohn's disease treated with azathioprine: Case report

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 2, 2003, Pages 185-187

  Li, Andy C Y ^a   Warnakulasuriya, Saman ^b   Thompson, Richard P H ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Azathioprine; Inflammatory bowel disease; Oral cancer

Indexed keywords

AZATHIOPRINE; CALCICHEW D3; CALCIUM; COLECALCIFEROL; MESALAZINE; OLSALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BIOPSY; BONE DENSITY; CANCER SUSCEPTIBILITY; CARCINOMA IN SITU; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENTERITIS; HUMAN; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR; TREATMENT OUTCOME;

ADULT; ANTIMETABOLITES; AZATHIOPRINE; CARCINOMA IN SITU; CROHN DISEASE; HUMANS; MALE; MOUTH MUCOSA; TONGUE NEOPLASMS;

EID: 0344406997     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200302000-00013     Document Type: Article

References (23)

1. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for remaining remission of Crohn's disease [Cochrane review]. In: The Cochrane Library. Issue 3. Oxford: Update Software; 2002.
2. Pearson DC, May GR, Fick G, Suthedand, LR, Azathioprine for maintainance of remission in Crohn's disease [Cochrane review]. In: The Cochrane Library. Issue 3. Oxford: Update Software; 2002.
3. Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB, Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 1991; 18:809-814.
4. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343:1249-1252.
5. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47: 988-992.
6. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999; 26:1705-1714.
7. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342:1514-1516.
8. Farrell RJ, Ang Y, Kileen P, O'Briain DS, Kelleher D, Keeling PW, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000; 47:514-519.
9. Fraser AG, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine - a 30 year study [abstract]. Gastroenterology 2000; 118:A254.
10. Dayharsh GA, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122:72-77.
11. King GN, Healy CM, Glover MT, Kwan JTC, Williams DM, Leigh IM, et al. Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med 1995; 332:1052-1057.
12. Bottomley WW, Ford G, Cunliffe WJ, Cotterill JA. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br J Dermatol 1995; 133:460-462.
13. Dalton A, Curtis D, Harrington CI. Synergistic effects of azathioprine and ultraviolet light detected by sister chromatid exchange analysis. Cancer Genet Cytogenet 1990; 45:93-99.
14. Austin AS, Spiller RC. Inflammatory bowel disease, azathioprine and skin cancer: case report and literature review. Eur J Gastroenterol Hepatol 2001; 13:193-194.
15. Forbes A, Reading NG. Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. Aliment Pharmacol Ther 1995; 9:465-470.
16. Cancer Research Campaign. CancerStats; Oral-UK. London: CRC; 2002. pp. 1-10.
17. Llewellyn CD, Johnson NW, Warnakulasuriya KAAS. Risk factors for squamous cell carcinoma of the oral cavity in young people - a comprehensive literature review. Oral Oncol 2001; 37:401-418.
18. Johnson NW, Warnakulasuriya KAAS Epidemiology and etiology of oral cancer in the United Kingdom. Comm Dent Health 1993; 10 (Suppl 1):13-19.
19. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336:897-904.
20. Varga E, Tyldesley WR. Carcinoma arising in cyclosporin-induced gingival hyperplasia. Br Dent J 1991; 171:26-27.
21. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347:215-219.
22. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50:485-489.
23. Fraser AG, Orchard TR, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002; 16:1225-1232.